Literature DB >> 32506289

Resected High-Risk Rectal GIST Harboring NTRK1 Fusion: a Case Report and Review of the Literature.

Renata D'Alpino Peixoto1, Bruno Amaral Medeiros2, Eduardo Henrique Cronemberger3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 32506289     DOI： 10.1007/s12029-020-00423-x

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  10 in total

1.  Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.

Authors:  Monica Brenca; Sabrina Rossi; Maurizio Polano; Daniela Gasparotto; Lucia Zanatta; Dominga Racanelli; Laura Valori; Stefano Lamon; Angelo Paolo Dei Tos; Roberta Maestro
Journal:  J Pathol       Date:  2016-01-25       Impact factor: 7.996

2.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.

Authors:  David S Hong; Steven G DuBois; Shivaani Kummar; Anna F Farago; Catherine M Albert; Kristoffer S Rohrberg; Cornelis M van Tilburg; Ramamoorthy Nagasubramanian; Jordan D Berlin; Noah Federman; Leo Mascarenhas; Birgit Geoerger; Afshin Dowlati; Alberto S Pappo; Stefan Bielack; François Doz; Ray McDermott; Jyoti D Patel; Russell J Schilder; Makoto Tahara; Stefan M Pfister; Olaf Witt; Marc Ladanyi; Erin R Rudzinski; Shivani Nanda; Barrett H Childs; Theodore W Laetsch; David M Hyman; Alexander Drilon
Journal:  Lancet Oncol       Date:  2020-02-24       Impact factor: 41.316

3.  Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.

Authors:  Sosipatros A Boikos; Alberto S Pappo; J Keith Killian; Michael P LaQuaglia; Chris B Weldon; Suzanne George; Jonathan C Trent; Margaret von Mehren; Jennifer A Wright; Josh D Schiffman; Margarita Raygada; Karel Pacak; Paul S Meltzer; Markku M Miettinen; Constantine Stratakis; Katherine A Janeway; Lee J Helman
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

Review 4.  Gastrointestinal stromal tumour.

Authors:  Heikki Joensuu; Peter Hohenberger; Christopher L Corless
Journal:  Lancet       Date:  2013-04-24       Impact factor: 79.321

Review 5.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

6.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

7.  Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.

Authors:  Olivier Mir; Claire Cropet; Maud Toulmonde; Axel Le Cesne; Mathieu Molimard; Emmanuelle Bompas; Philippe Cassier; Isabelle Ray-Coquard; Maria Rios; Antoine Adenis; Antoine Italiano; Olivier Bouché; Emmanuelle Chauzit; Florence Duffaud; François Bertucci; Nicolas Isambert; Julien Gautier; Jean-Yves Blay; David Pérol
Journal:  Lancet Oncol       Date:  2016-04-05       Impact factor: 41.316

Review 8.  Gastrointestinal stromal tumour.

Authors:  Brian P Rubin; Michael C Heinrich; Christopher L Corless
Journal:  Lancet       Date:  2007-05-19       Impact factor: 79.321

9.  Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.

Authors:  Chi Tarn; Lori Rink; Erin Merkel; Douglas Flieder; Harsh Pathak; Daphne Koumbi; Joseph R Testa; Burton Eisenberg; Margaret von Mehren; Andrew K Godwin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-11       Impact factor: 11.205

10.  BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.

Authors:  G S Falchook; J C Trent; M C Heinrich; C Beadling; J Patterson; C C Bastida; S C Blackman; R Kurzrock
Journal:  Oncotarget       Date:  2013-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.